Description

Pertuzumab Injection 420 mg (r-DNA Origin) is a recombinant humanized monoclonal antibody designed to target the human epidermal growth factor receptor 2 (HER2). It is commonly used in combination with trastuzumab and chemotherapy for the treatment of HER2-positive breast cancer.

🔬 Mechanism of Action

Pertuzumab binds to a different epitope of the HER2 receptor than trastuzumab, preventing HER2 dimerization (pairing with other HER receptors). This dual HER2 blockade results in:

• Inhibition of tumor cell growth
• Reduced cancer cell survival
• Enhanced anti-tumor activity when combined with trastuzumab

💊 Indications

Pertuzumab 420 mg is indicated for:

• HER2-positive metastatic breast cancer
• Neoadjuvant treatment of HER2-positive early breast cancer
• Adjuvant treatment of HER2-positive early breast cancer

It is typically administered in combination with trastuzumab and chemotherapy agents under oncologist supervision.

📌 Key Features of Pertuzumab Injection 420 mg

• Strength: 420 mg
• Dosage Form: Intravenous infusion
• Therapeutic Class: Anti-HER2 Monoclonal Antibody
• Origin: Recombinant DNA technology
• Administration: IV infusion in a hospital or oncology setting
• Monitoring: Cardiac function monitoring required during treatment

⚕️ Benefits of Pertuzumab

• Dual HER2 blockade when combined with trastuzumab
• Improves progression-free survival
• Enhances response rates in early and metastatic settings
• Established role in standard HER2-positive breast cancer regimens

⚠️ Precautions

• Risk of infusion-related reactions
• Cardiac monitoring required due to potential left ventricular dysfunction
• Not recommended during pregnancy
• Use strictly under oncologist supervision

Pertuzumab Injection 420 mg (r-DNA Origin) provides an advanced targeted treatment option for HER2-positive breast cancer, supporting improved clinical outcomes through dual HER2 pathway inhibition when used as part of a comprehensive oncology treatment plan.